Taiyi Liangsheng Raises Over 1 Billion Yuan, Accelerating Toward Large-Scale Fault-Tolerant Quantum Computing
Building Differentiated Quantum Computing System Capabilities from a Fault-Tolerant Endgame Perspective
Articles
One Dish, Two Coffee Meetings: How a Stir-Fry Robot Goes Global｜Finance Toutiao X Yu Chen X Qianyi Intelligence
Why Do Cooking Robots Have Trillion-Yuan Potential?
First Batch of Investment Reviewers Unveiled, Calling Hong Kong Sci-Tech Youth to Apply | Yunqi Partners X Shanghai Qidian Community
Future Starting Point "Hong Kong Season" is now open for applications.
WEFLY Closes Nearly 100 Million Yuan Funding Round, Crewed eVTOL Receives TC Application Acceptance | Linear Portfolio
Officially entered the airworthiness certification phase.
Heart Capital's Yan Han: AI Goes Beyond Frontier Models, the Future Belongs to the Real World | VOICE
When AI becomes infrastructure, who will create the next wave of value?
What Should We Actually Learn in the Age of AI? | A Conversation with Yu Hong: Three Timeless Abilities
White Rhino Closes $100 Million Series C, Extending Lead in Autonomous Freight | Linear Portfolio
Accelerating the world's transition to the era of driverless vehicles.
Shandong Rebel, a King Who Won't Kneel
Young people who "haven't accomplished a single thing of note, yet have already figured out how they'll be remembered as great."
Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines
On October 9, 2026, **Dalton Venture portfolio company Triastek (Nanjing) Pharmaceutical Technology Co., Ltd.** (hereinafter referred to as "Triastek" or "the Company") announced that **the Company and its wholly-owned subsidiary Triastek (Shanghai) Pharmaceutical Technology Co., Ltd. have entered into a collaboration and license agreement with Johnson & Johnson**. The two parties will combine Johnson & Johnson's expertise in pharmaceutical development with Triastek's
TRAE Says It Built This Desk
Back to basics